Pardoprunox hydrochloride

• CAT Number: I002926
• CAS Number: 269718-83-4
• Molecular Formula: C12H16ClN3O2
• Molecular Weight: 269.73
• Purity: ≥95%
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: 2°C to 8°C
• IC50: 8.1/8.6/8.5 (pKi, for D2/ D3/5-HT1A receptor)
• IUPAC Name: 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one;hydrochloride
• InChI: 1S/C12H15N3O2.ClH/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9;/h2-4H,5-8H2,1H3,(H,13,16);1H
• InChIKey: NQRIKTDKFHAOKC-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3.Cl

Pardoprunox hydrochloride (Cat No.: I002926) is a partial dopamine D₂/D₃ receptor agonist and 5-HT1A receptor agonist developed for Parkinson’s disease and other neurological disorders. It modulates dopaminergic and serotonergic pathways, offering potential benefits for motor symptoms and neuropsychiatric conditions. With its unique receptor profile, pardoprunox aims to provide symptom relief while minimizing side effects like dyskinesia. Although clinical trials explored its efficacy in Parkinson’s disease and depression, further research is needed to establish its therapeutic potential and long-term safety.

Reference

[1]. Glennon JC, et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse. 2006 Dec 15;60(8):599-608.

[2]. Jones CA, et al. An in vivo pharmacological evaluation of pardoprunox (SLV308)–a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson/’s disease. Eur Neuropsychopharmacol. 2010 Aug;20(8):582-593.